RAPT Therapeutics (RAPT) has released an update.
RAPT Therapeutics, Inc. has encountered a setback as the FDA imposed a clinical hold on their Phase 2b and Phase 2a trials for zelnecirnon, due to a severe liver failure incident in a patient, which might be linked to the drug. The company has ceased dosing and new participant enrollment in the trials for atopic dermatitis and asthma, while their separate oncology trial for a different drug remains unaffected.
For further insights into RAPT stock, check out TipRanks’ Stock Analysis page.
